BioLink Weekly

AstraZeneca Returns to CSPC in a $1.77B siRNA Kidney Pact as Takeda Bets Up to $600M on Insilico's AI Discovery Engine

The June 30 to July 7 window was carried by two China-linked platform licenses rather than clinical-asset buyouts. AstraZeneca went back to its go-to Chinese partner CSPC Pharmaceutical (announced July 3) in a collaboration worth up to $1.77B - $30M upfront, up to $540M in development and regulatory milestones and up to $1.2B in commercial milestones - to discover siRNA therapies for two undisclosed chronic kidney-disease pathways, with extrahepatic (renal) delivery as the technical frontier. A day earlier (July 2), Takeda signed an AI drug-discovery pact with Hong Kong-based Insilico Medicine worth up to about $600M (about $60M in project-initiation and near-term payments plus later milestones and tiered royalties), with Insilico's Pharma.AI platform leading early discovery and Takeda taking worldwide rights to selected candidates. No major M&A (control transaction) was announced in-window, following a heavy late-June cluster. On the science side, the FDA approved Orca Bio's Tregzi (Orca-T) as the first precision-engineered cell therapy for allogeneic transplant (June 30) and expanded Vertex/CRISPR's Casgevy to children aged 2 and older with sickle cell disease (July 1), with Vera Therapeutics' atacicept facing a July 7 FDA decision in IgA nephropathy.

In This Issue

• Licensing / China-out
• RNA / siRNA
• AI Drug Discovery
• Cell & Gene Therapy
• Regulatory
• BD&L Mandates